Home> News

  • China's action on rare diseases inspires hope among patients

    2024-07-19

    In order to address the patients' needs, China's National Medical Products Administration (NMPA) gives priority to such drugs in assessment and approval procedures, said Geng Ying, an official of the NMPA Center for Drug Evaluation.

  • Xu Jinghe meets with Vice Minister Curative Care of Dutch Ministry of Health, Welfare and Sport

    2024-07-04

    Xu Jinghe, Deputy Commissioner of China's National Medical Products Administration (NMPA), met with the Dutch delegation in Beijing on June 24.

  • NMPA holds special training sessions on GRP, RPI

    2024-07-04

    From June 19 to 26, the National Medical Products Administration (NMPA) invited experts from the World Health Organization (WHO) to hold special training sessions on Good Regulatory Practices (GRP) and Regulatory Performance Indicators (RPI) in Kunming, Southwest China's Yunnan province.

  • Xu Jinghe meets with Acting Director of Indonesia’s BPOM

    2024-07-04

    On June 27, Xu Jinghe, Deputy Commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Rizka Andalucia, Acting Director of Indonesia's food and drug authority BPOM, also the Director-general of Pharmaceutical and Medical Devices of the Indonesian Ministry of Health.

  • China's quantity and quality of innovative drugs joins global lead

    2024-06-19

    Huang Guo, deputy director of the National Medical Products Administration, said that from January to May of this year, a total of 20 innovative medicines and 21 innovative medical equipment have gained market approval on the mainland.

  • NMPA holds meetings on vaccine regulatory QMS

    2024-06-19

    The National Medical Products Administration (NMPA) held meetings on the construction of the vaccine regulatory quality management system (QMS) in Nanjing, Jiangsu province, and Urumqi, Xinjiang Uygur autonomous region, on May 16 and May 30, respectively, in a bid to enhance the construction of the QMS and facilitate the cohesion and coordination of the QMS in the vaccine regulatory system.

< 1 2 3 4 5 ... 200 >